azimilide
DISEASE INTERVENTION COMPARISON RESULTS
Am Heart J. 2006 May;151(5):1043-9 Randomized Controlled Trial
IN StudyID: A-COMET-I 2006, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To maintain sinus rhythm or modify death at 6 months. Azimilide caused more adverse events and pro-arrhythmia
Eur Heart J. 2006 Sep;27(18):2224-31. Epub 2006 Aug 25 Randomized Controlled Trial
IN StudyID: A-COMET-II 2006, atrial fibrillation The Use of
azimilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To prevent, at 6 months, AF recurrence without being stopped because adverse effects: sotalol 33% VS 19% azim VS 15% placebo. Both azimilide and sotalol increased proarrhythmia.
J Am Coll Cardiol. 2000 Sep;36(3):794-802 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence - at ? Time
Am J Cardiol. 2001 Nov 1;88(9):974-9 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, pro-arrhythmia - at 6 months
Am Heart J. 2003 Sep;146(3):489-93 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To symptoms at AF recurrence, adverse effects - at 6 months
Am Heart J. 2002 Apr;143(4):643-9 Randomized Controlled Trial
IN StudyID: ASAP 2003 (subordinated publication), atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
Circulation. 2003 Mar 4;107(8):1141-5 Randomized Controlled Trial
IN StudyID: ASAP 2003, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects - at 6 months
Am J Cardiol. 2006 Jul 15;98(2):215-8 Randomized Controlled Trial
IN StudyID: A-START 2006, atrial fibrillation, paroxysmal or recent-onset The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To modify time to AF recurrence. Azimilide increased adverse effects and pro-arrhytmia. No deats were reported
J Cardiovasc Electrophysiol. 2008 Feb;19(2):172-7 Randomized Controlled Trial
IN StudyID: SVA-4, atrial fibrillation The Use of
azimilide
As Treatment, Chronic
Is equal Than
placebo
To modify, at 6 months, mortality or Af recurrence, while increasing adverse effects and pro-arrhythmia